Abstract
In esophageal cancer, molecular markers representing tumor biological properties or patient features could provide significant determinants for predicting therapeutic response. To date, however, there is no sufficient evidence that current diagnostic methods can be used to improve the efficacy of multimodality neoadjuvant therapies. Molecular research in esophageal cancer has focused on two principal categories: (1) mRNA from cancer biopsies, searching for a relationship between outcome and the different gene expression levels; (2) DNA from healthy tissues, searching for associations between outcome and constitutive inter-individual genetic variations. This second option is a very attractive one, in that a small volume of peripheral blood is sufficient to obtain genomic DNA from lymphocytes-monocytes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Luthra R, Wu T, Luthra MG et al (2006) Gene expression profiling of localized esophageal carcinomas: association with pathologic response to preoperative chemoradiation. J Clin Oncol 24:259–267
Luthra MG, Ajani JA, Izzo J et al (2007) Decreased expression of gene cluster at chromosome1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 13:912–919
Duong C, Greenawalt DM, Kowalczyk A et al (2007) Pretreatment gene expression profiles can be used to predict response to neoadjuvant chemoradiotherapy in esophageal cancer. Ann Surg Oncol 14:3602–3609
Maher SG, Gillham CM, Duggan SP et al (2009) Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann Surg 250:729–737
Warnecke-Eberz U, Metzger R, Bollschweiler E et al (2010) TaqMan low-density arrays and analysis by artificial neuronal networks predict response to neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 11:55–64
Metzger R, Heukamp L, Drebber U et al (2010) CUL2 and STK11 as novel response-predictive genes for neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics 11:1105–1113
Kim SM, Park YY, Park ES et al (2010) Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One 5:e15074
Warnecke-Eberz U, Vallböhmer D, Alakus H et al (2009) ERCC1 and XRCC1 gene polymorphisms predict response to neoadjuvant radiochemotherapy in esophageal cancer. J Gastrointest Surg 13:1411–1421
Wu X, Gu J, Wu TT et al (2006) Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer. J Clin Oncol 24:3789–3798
Gusella M, de Manzoni G, Marinelli R et al (2009) XPA and XRCC3 gene polymorphisms predict survival in esophageal cancer patients receiving neo-adjuvant radio-chemotherapy with cisplatin (CDDP), docetaxel (DTX) and 5-fluorouracil (FU). J Clin Oncol 27:e14571
Okuno T, Tamura T, Yamamori M et al (2007) Favorable genetic polymorphisms predictive of clinical outcome of chemoradiotherapy for stage II/III esophageal squamous cell carcinoma in Japanese. Am J Clin Oncol 30:252–257
Liao Z, Liu H, Swisher SG et al (2006) Polymorphism at the 3′-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 64:700–708
Sarbia M, Stahl M, von Weyhern C et al (2006) The prognostic significance of genetic polymorphisms (Methylenetetrahydrofolate Reductase C677T, Methionine Synthase A2756G, Thymidilate Synthase tandem repeat polymorphism) in multimodally treated oesophageal squamous cell carcinoma. Br J Cancer 94:203–207
Jain M, Kumar S, Upadhyay R et al (2007) Influence of apoptosis (BCL2, FAS), cell cycle (CCND1) and growth factor (EGF, EGFR) genetic polymorphisms on survival outcome: an exploratory study in squamous cell esophageal cancer. Cancer Biol Ther 6:1553–1558
Jatoi A, Martenson JA, Foster NR et al (2007) Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044). Am J Clin Oncol. 30:507–513
Lanuti M, Liu G, Goodwin JM et al (2008) A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome. Clin Cancer Res 14:3216–3222
Alakus H, Warnecke-Eberz U, Bollschweiler E et al (2009) GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics J 9:202–207
Bachmann K, Shahmiri S, Kaifi J et al (2009) Polymorphism Arg290Arg in esophageal-cancer-related gene 1 (ECRG1) is a prognostic factor for survival in esophageal cancer. J Gastrointest Surg 13:181–187
Bradbury PA, Zhai R, Ma C et al (2009) Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res 15:4680–4685
Bradbury PA, Kulke MH, Heist RS et al (2009) Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics 19:613–625
Bradbury PA, Zhai R, Hopkins J et al (2009) Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis. 30:793–798
Cescon DW, Bradbury PA, Asomaning K et al (2009) p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis. Clin Cancer Res 15:3103–109
Hildebrandt MA, Yang H, Hung MC et al (2009) Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol. 27:857–871
Narumiya K, Metzger R, Bollschweiler E et al (2011) Impact of ABCB1 C3435T polymorphism on lymph node regression in multimodality treatment of locally advanced esophageal cancer. Pharmacogenomics 12:205–214
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Italia
About this chapter
Cite this chapter
Gusella, M., Pasini, F., de Manzoni, G. (2012). Role of Molecular Biology in the Prediction of Response to Neoadjuvant Treatment. In: de Manzoni, G. (eds) Treatment of Esophageal and Hypopharyngeal Squamous Cell Carcinoma. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-2330-7_7
Download citation
DOI: https://doi.org/10.1007/978-88-470-2330-7_7
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-2329-1
Online ISBN: 978-88-470-2330-7
eBook Packages: MedicineMedicine (R0)